
Claims

1. A pharmaceutical combination comprising an atypical antipsychotic drug and a GlyT1 receptor antagonist of formula



I

wherein

Ar is a substituted 6-membered heteroaryl group, containing one, two or three nitrogen atoms, and wherein the heteroaryl groups may be substituted by one or more substituents selected from the group consisting of halogen, $(C_1\text{-}C_6)$-alkyl or $(C_1\text{-}C_6)$-alkyl substituted by halogen;

R^1 is hydrogen or $(C_1\text{-}C_6)$-alkyl;

R^2 is $(C_1\text{-}C_6)$-alkyl substituted by halogen,

R^3, R^4 and R^6 are independently from each other hydrogen, halogen, $(C_1\text{-}C_6)$-alkyl or $(C_1\text{-}C_6)$-alkoxy;

R^5 is SO_2R^{10};

R^{10} is $(C_1\text{-}C_6)$-alkyl optionally substituted by halogen,

and pharmaceutically acceptable acid addition salts thereof, as well as enantiomeric forms thereof.

2. A pharmaceutical combination according to claim ~~2~~ 1 comprising an atypical antipsychotic drug, selected from the group consisting of risperidone, paliperidone, olanzapine, aripiprazole, quetiapine or ziprasidone and a GlyT1 receptor antagonist selected from rac-[4-(3-chloro-5-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl]-[5-methanesulfonyl-2-(2,2,2-trifluoro-1-methyl-ethoxy)-phenyl]-methanone,
rac-[5-methanesulfonyl-2-(2,2,2-trifluoro-1-methyl-ethoxy)-phenyl]-[4-(5-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl]-methanone,
rac-[4-(5-bromo-pyridin-2-yl)-piperazin-1-yl]-[5-methanesulfonyl-2-(2,2,2-trifluoro-1-methyl-ethoxy)-phenyl]-methanone,
rac-[4-(3-fluoro-5-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl]-[5-methanesulfonyl-2-(2,2,2-